TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01173328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pursed-lip breathing
Description: Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Breathing
Study: NCT02054572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]Etelcalcetide
Description: 750 nCi of \[¹⁴C\]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
Study: NCT02898792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted infusion of remifentanil
Description: Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted infusion of remifentanil
Description: Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted infusion of remifentanil
Description: Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
Study: NCT01164956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Study: NCT02192762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Withdrawal regulation training
Description: Withdrawal coping skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation training
Description: Relaxation skills instruction
Study: NCT01064609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy with conventional forceps
Description: Transbronchial lung biopsy with conventional forceps.
Study: NCT02715388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlasScope Surgical Microscope
Description: 3D visualization of the poterior chamber for silicon oil removal
Study: NCT02936544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code:Z09-054)
Study: NCT00714766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular volume administration
Description: Infusion of colloid to reestablish CVP under heat stress
Study: NCT04922931

Intervention type: PROCEDURE
Intervention: scheduled surgery
Description: Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia

Intervention type: PROCEDURE
Intervention: scheduled surgery
Description: Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia
Study: NCT03661398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Description: All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
Study: NCT00439686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-201
Description: ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
Study: NCT01785056

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Privigen
Description: Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Privigen
Description: Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
Study: NCT01584648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: Dabrafenib 150 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg once daily
Study: NCT06235762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: This clinical trial evaluate the effects of nutritional intervention (individualized and personalized for each patient) on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus
Study: NCT02267330

Intervention type: PROCEDURE
Intervention: Exposure Recording
Description: Patient undergoing fracture surgery will have radiation exposure recorded
Study: NCT02156544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519
Study: NCT01164956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02156544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519
Study: NCT01584648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib placebo
Description: Dabrafenib 150 mg twice daily and trametinib placebo
Study: NCT00059826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interferon-alfa-2b
Description: IV
Study: NCT02938975

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Army combat uniform
Description: Army combat uniform with no permethrin
Study: NCT05433233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Participants will perform 3,000 additional steps/day on 5 days/week.
Study: NCT02156544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT04149860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF87908
Description: Lu AF87908 concentrate for solution for intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF87908
Description: Lu AF87908 concentrate for solution for intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF87908
Description: Lu AF87908 concentrate for solution for intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Concentrate for solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Concentrate for solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Concentrate for solution for IV infusion
Study: NCT04026269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOAP
Description: the new chemotherapy regimen for r/r cHL
Study: NCT02896036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Veress needle entry with concomitant CO2
Description: The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Veress needle entry with subsequent CO2
Description: A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
Study: NCT00678535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m\^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT01760473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal challenge drug
Description: Each of the experimental challenge drugs were administered intranasally to all participants in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal challenge drug
Description: Each of the experimental challenge drugs were administered intranasally to all participants in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal challenge drug
Description: Each of the experimental challenge drugs were administered intranasally to all participants in random order.
Study: NCT01164956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00366145

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal®
Description: 2 infusions of 2 million cells/kg per week for 4 weeks
Study: NCT00059826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00366145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 infusions per week for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care for GVHD
Description: Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care for GVHD
Description: Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)
Study: NCT03421821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Subfascial injection OR extrafascial injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Subfascial injection OR extrafascial injection
Study: NCT03026608

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Veggie Van Program
Description: This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veggie Van Program
Description: This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
Study: NCT02505230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating
Description: Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating
Description: Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
Study: NCT02792738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnosis
Study: NCT01933945

Intervention type: PROCEDURE
Intervention: TACE (transarterial chemoembolization)
Description: First treatment for all patients included in the study

Intervention type: PROCEDURE
Intervention: TACE (transarterial chemoembolization)
Description: First treatment for all patients included in the study

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Study: NCT03917186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: administration of sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: administration of Desflurane
Study: NCT05433233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Participants will perform 3,000 additional steps/day on 5 days/week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAPA Behavior Change Counseling
Description: Structured dialogue for initiating behavior change.
Study: NCT01227252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: 5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
Study: NCT02566226

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine with normal saline
Description: Isobaric bupivacaine 15 mg + normal saline 0.5 cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with intrathecal morphine
Description: Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
Study: NCT02610179

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Glucola GCT
Description: Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Twizzlers challenge
Description: Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
Study: NCT03021421

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: intratechal (subarachnoidal )injection
Description: 10 mg (2 cc) intrathecal single shot injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lombar plexus and sciatic nerve injection
Description: USG -guided lumbar plexus visualised and 20 ml local anaesthetic mixture (15 cc %0,5 Bupivacaine Hydrochloride 5 cc and %2 Lidocaine 5 cc ) for lombar plexus single shot injection
Study: NCT04850690

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Gait analysis
Description: The gait with four different conditions (single gait, Cognitive Task, Motor Task and Cognitive Task\&Motor Task) was evaluated by Kinovea video analysis method on a 10-meter course.~* Single: Walking without task at a self-selected speed~* Cognitive Task (CT): Walking while counting down rhythmically from 20 in threes~* Motor Task (MT): Walking while carrying an empty box~* CT + MT: Walking while carrying an empty box and counting down rhythmically from 20 in threes
Study: NCT02545790

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: 2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: 2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.

Intervention type: BIOLOGICAL
Intervention: Serology
Description: protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.

Intervention type: BIOLOGICAL
Intervention: Serology
Description: protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
Study: NCT02529514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: 25 mg for 7 days at 10 pm every day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 7 days at 10 pm every day
Study: NCT04615923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: Administration: Oral~Dose: 45mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Administration: Oral~Dose: one capsule twice daily
Study: NCT04090645

Intervention type: DEVICE
Group type: OTHER
Intervention: TheraSphere
Description: TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
Study: NCT00617045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: Total treatment period is 12 weeks~30mg po qd times 1 week~60mg po qd times 11 weeks
Study: NCT00847054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-004 (monoclonal antibody to TEM1)
Description: Intravenous administration
Study: NCT01227252

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules, daily for 14 days
Study: NCT04562233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-delivered physical activity intervention.
Description: Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Printed, individualized resistance-based physical activity program.
Description: Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
Study: NCT01760473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal challenge drug
Description: Each of the experimental challenge drugs were administered intranasally to all participants in random order.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal challenge drug
Description: Each of the experimental challenge drugs were administered intranasally to all participants in random order.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intranasal challenge drug
Description: Each of the experimental challenge drugs were administered intranasally to all participants in random order.
Study: NCT01237262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab, etanercept, infliximab
Description: Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.~Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks.
Study: NCT02525991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Staccato® Delivery System Loxapine (ADASUVE®)
Description: one dose Loxapine Staccato 9.1 mg
Study: NCT02047201

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Assessing tumor response using FDG-PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
Study: NCT01093781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
Study: NCT03968159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2×placebo tablets \[size- and color-matched to pimavanserin\]) administered orally as a single dose once daily
Study: NCT01124227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icodextrin
Description: 2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
Study: NCT01724086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805
Description: Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.